



August 26, 2015

Gene Techno Science Co., Ltd.  
Code: 4584 (TSE Mothers)  
President  
Masanari Kawaminami

### Announcement of Revision of the Operational Guideline

Gene Techno Science Co., Ltd. (“Company”) announced the revision of Operational Guideline for the second quarter of the fiscal year 2015 (April to September 2015, accumulated) released in the summary of the Company’s financial statement dated May 14, 2015. The annual Operational Guideline for the whole fiscal year 2015 has no change.

**The revision of non-consolidated Operational Guideline at the end of the second quarter of the fiscal year 2015 (from April 1, 2015 to September 30, 2015, accumulated)**

(Unit: Million Japanese Yen)

	Net sales	Operating income	Ordinary income	Net income	EPS
Original Guideline (A)	681	(-)150	(-)136	(-)137	(-)56.09
Revised Guideline (B)	781	(-)150	(-)136	(-)137	(-)56.09
Difference (B)-(A)	100	-	-	-	
Difference %	14.7	-	-	-	
Reference: the same period of the previous year (2014 2Q)	145	(-)396	(-)369	(-)370	(-)155.51

Background:

The sales of the second quarter increased due to strong sales of our marketed biosimilar product and the milestone payment revenue (50 million Japanese Yen) under the MOU with Mochida Pharmaceutical Co., Ltd. regarding Collaboration for Biosimilar project in anti-cancer field which was released on August 11, 2015.

The forecast of income and expenses is not revised since the Company anticipates

expenses to accelerate the research and development of its biosimilar products.

(Caution: The revision and other future perspectives are sole judgement of the Company based on information available and hypothesis which the Company judges rational. The actual performance may vary due to various factors.)

Media Contact:

E-mail: [info@g-gts.com](mailto:info@g-gts.com)

Masaki Okusawa

Tel: 81-3-3517 1353